{"slug":"kras","tag":"kras","variants":["kras"],"description":"No description yet","count":4,"kinds":{"person":1,"biomarker":3},"related":[{"slug":"biomarker","tag":"biomarker","shared":3},{"slug":"lung","tag":"lung","shared":1},{"slug":"negative-selector","tag":"negative-selector","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1}],"records":[{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","tldr":"Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy."},{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/","tldr":"KRAS G12C swaps glycine 12 for cysteine and was the first KRAS mutation a drug could grip. Sotorasib and adagrasib are approved for it in lung cancer, and with an EGFR antibody in bowel cancer."},{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/","tldr":"RAS wild-type is the absence of a mutation, and it is the result that decides whether the EGFR antibodies cetuximab and panitumumab can be given in bowel cancer. Extended testing means KRAS and NRAS exons 2, 3 and 4, not just codons 12 and 13."},{"id":"kras-g12d","kind":"biomarker","name":"KRAS G12D (and other non-G12C KRAS mutations)","route":"/biomarkers/kras-g12d/","tldr":"G12D is the commonest KRAS mutation, especially in pancreatic cancer, and has no approved drug yet. In bowel cancer any KRAS or NRAS mutation is a reason not to give EGFR antibodies, which is where the approvals sit."}]}